<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-9933</journal-id>
<journal-title><![CDATA[Revista Información Científica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. inf. cient.]]></abbrev-journal-title>
<issn>1028-9933</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas Guantánamo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-99332019000100077</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores de riesgo en complicaciones tromboembólicas cerebrales de pacientes con fibrilación auricular permanente no valvular]]></article-title>
<article-title xml:lang="en"><![CDATA[Risk factors in cerebral thromboembolic complications in patients with non-valvular permanent atrial fibrillation]]></article-title>
<article-title xml:lang="pt"><![CDATA[Fatores de risco em complicações tromboembólicas cerebrais em pacientes com fibrilação atrial permanente não valvuvar]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Goire Guevara]]></surname>
<given-names><![CDATA[Geordan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuza Díaz]]></surname>
<given-names><![CDATA[Lázaro Artemio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fournier Calzado]]></surname>
<given-names><![CDATA[Giorbis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Marrero]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montero Vega]]></surname>
<given-names><![CDATA[Varinia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente &#8220;Dr. Agostinho Neto&#8221;  ]]></institution>
<addr-line><![CDATA[ Guantánamo]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2019</year>
</pub-date>
<volume>98</volume>
<numero>1</numero>
<fpage>77</fpage>
<lpage>87</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-99332019000100077&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-99332019000100077&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-99332019000100077&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: la fibrilación auricular es la arritmia cardiaca más frecuente que se trata en la práctica clínica y produce un 33 % de las hospitalizaciones asociadas a arritmias.  Objetivo:  identificar factores de riesgo de complicaciones tromboembólicas cerebrales en pacientes con fibrilación auricular permanente no valvular y tratamiento anticoagulante oral entre los años 2015 y 2018.  Método: se realizó un estudio de casos y controles en el Hospital General Docente &#8220;Dr Agostinho Neto&#8221; en el periodo octubre entre 2015 y abril del 2018. El universo estuvo conformado 213 pacientes, 71 casos con fibrilación auricular permanente que sufrieron complicaciones tromboembólicas cerebrales bajo tratamiento con warfarina y 142 controles con fibrilación auricular permanente, con igual, pero sin las complicaciones antes mencionadas. Se seleccionaron dos controles por cada caso (2:1) para incrementar el poder estadístico del estudio. Se analizaron variables sociodemográficas, clínicas, ecocardiográficas, labilidad del INR (índice internacional normalizado) y adherencias terapéuticas. El análisis de los datos se presentó en tablas de datos de doble entrada. Se estimaron Chi cuadrado, Intervalos de Confianza y Odds ratio.  Resultados:  resultaron significativas el grupo de edad de 75 o más años, el sexo masculino, la hipertensión arterial, la presencia de placas de ateromas en aorta y carótidas, la diabetes mellitus, el INR subóptimo, la mala adherencia terapéutica.  Conclusiones: el grupo etario de 75 o más años, sexo masculino, fumar, hipertensión arterial, diabetes mellitus, placas de ateroma en aorta y carótidas, INR subóptimo y mala adherencia terapéutica constituyen factores de riesgo significativos para la aparición de complicaciones tromboembólicas cerebrales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  atrial fibrillation is the most frequent cardiac arrhythmia that is treated in clinical practice and produces 33% of hospitalizations associated with arrhythmias.  Objective:  to identify risk factors for cerebral thromboembolic complications in patients with permanent non-valvular atrial fibrillation and oral anticoagulant treatment between 2015 and 2018.  Method:  a case-control study was conducted in the General Teaching Hospital "Dr Agostinho Neto" in the period October between 2015 and April 2018. The universe consisted of 213 patients, 71 cases with permanent atrial fibrillation who suffered cerebral thromboembolic complications under treatment with warfarin and 142 controls with permanent atrial fibrillation, with the same, but without the aforementioned complications. Two controls were selected for each case (2: 1) to increase the statistical power of the study. We analyzed sociodemographic, clinical, echocardiographic variables, lability of the INR (international normalized index) and therapeutic adhesions. The analysis of the data was presented in double entry data tables. Chi square, Confidence Intervals and Odds ratio were estimated.  Results:  the age group of 75 or more years, the male sex, arterial hypertension, the presence of plaques of atheroma in the aorta and carotids, diabetes mellitus, suboptimal INR, poor therapeutic adherence were significant.  Conclusions:  the age group of 75 years or older, male sex, smoking, high blood pressure, diabetes mellitus, atheromatous plaques in the aorta and carotids, suboptimal INR and poor therapeutic adherence constitute significant risk factors for the appearance of cerebral thromboembolic complications.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  a fibrilação atrial é a arritmia cardíaca mais frequente que é tratada na prática clínica e produz 33% das internações associadas a arritmias.  Objectivo:  Para identificar os fatores de risco para as complicações tromboembólicas cerebrais em pacientes com não-valvular fibrilação atrial permanente e terapia anticoagulante oral, entre 2015 e 2018.  Método:  Um estudo de casos e controlos foi realizada no Hospital Universitario "Dr. Agostinho Neto" no período de outubro 2015 a abril de 2018. o grupo de estudo consistiu de 213 pacientes, 71 casos com fibrilação atrial permanente que sofreram sob cerebral complicações varfarina tromboembólica e 142 controles de fibrilação atrial permanente com igual, mas sem as complicações acima. Dois controles foram selecionados para cada caso (2: 1) para aumentar o poder estatístico do estudo. Foram analisadas variáveis sociodemográficas, clínicas, ecocardiográficas, labilidade do INR (índice internacional normalizado) e adesões terapêuticas. A análise dos dados foi apresentada em tabelas de dados de dupla entrada. Qui-quadrado, Intervalos de Confiança e Odds ratio foram estimados.  Resultados:  foram grupo significativo idade de 75 anos, sexo masculino, a hipertensão, a presença de placas ateromatosas nas artérias aorta e carótida, diabetes mellitus, INR sub-óptima, a baixa adesão.  Conclusões:  o grupo de idade de 75 anos, sexo masculino, fumar, hipertensão, diabetes mellitus, placas aterosclericas na aorta e carótida, INR sub-tima e a fraca adesão constituem factores de risco importantes para a ocorrência de complicações tromboembólicas cerebrais.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[warfarina]]></kwd>
<kwd lng="es"><![CDATA[INR]]></kwd>
<kwd lng="es"><![CDATA[adherencia terapéutica]]></kwd>
<kwd lng="en"><![CDATA[atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[warfarin]]></kwd>
<kwd lng="en"><![CDATA[INR]]></kwd>
<kwd lng="en"><![CDATA[therapeutic adherence]]></kwd>
<kwd lng="pt"><![CDATA[fibrilação atrial]]></kwd>
<kwd lng="pt"><![CDATA[varfarina]]></kwd>
<kwd lng="pt"><![CDATA[INR]]></kwd>
<kwd lng="pt"><![CDATA[adesão terapêutica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roger]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd-Jones]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart disease and stroke statistics 2012 update: A report from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>125</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e2-e220</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schnabel]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gona]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Beiser]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[McManus]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<page-range>154-62</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schnabel]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Christophersen]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis]]></article-title>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2016</year>
<volume>13</volume>
<page-range>321-32</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sposato]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Cipriano]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Saposnik]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz Vargas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Riccio]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Hachinski]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2015</year>
<volume>14</volume>
<page-range>377-87</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Lake]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Di Marco]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2012</year>
<volume>125</volume>
<page-range>603-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerra-García]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valladares-Carvajal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal-Valladares]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Quiñones]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo asociados a ictus cardioembólico en pacientes con fibrilación auricular no valvular]]></article-title>
<source><![CDATA[Rev Finlay]]></source>
<year>2018</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ictus cardioembólico: epidemiología]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2012</year>
<volume>27</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emdin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[CX]]></given-names>
</name>
<name>
<surname><![CDATA[Hsiao]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Woodward]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Odutayo]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2016</year>
<volume>532</volume>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Skjøth]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Overvad]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<page-range>832-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Benussi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kotecha]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ahlsson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Atar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Casadei]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2017</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Overvad]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Skjoth]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Albertsen]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2015</year>
<volume>46</volume>
<page-range>2168-74</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Chiou]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[See]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2014</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labreuche]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Deplanque]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Touboul]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bruckert]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Amarenco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis]]></article-title>
<source><![CDATA[Atherosclerosis]]></source>
<year>2010</year>
<volume>212</volume>
<page-range>9-15</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Björck]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Renlund]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
<name>
<surname><![CDATA[Wester]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Svensson]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Själander]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes in a Warfarin-Treated Population With Atrial Fibrillation]]></article-title>
<source><![CDATA[JAMA Cardiology]]></source>
<year>2016</year>
<volume>1</volume>
<page-range>172-80</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aziz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Corder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wolffe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Comerota]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care]]></article-title>
<source><![CDATA[J Vasc Surg]]></source>
<year>2011</year>
<volume>54</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1404-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
